Key result
Azilsartan medoxomil demonstrates superior blood pressure control and pleiotropic organoprotection compared to other ARBs.
Why the study?
Concomitant diabetes mellitus complicates cardiac disease management and affects antihypertensive therapy effectiveness, necessitating evaluation of pleiotropic effects of drugs like azilsartan medoxomil.
Does azilsartan medoxomil provide superior antihypertensive efficacy and organoprotective effects compared to other ARBs in patients with hypertension and diabetes mellitus?
Does azilsartan medoxomil provide superior antihypertensive efficacy and organoprotective effects compared to other ARBs in patients with hypertension and diabetes mellitus?
Azilsartan medoxomil may offer beneficial pleiotropic and organoprotective effects, including nephroprotection, in hypertensive patients with diabetes or metabolic syndrome.
Should not yet change ARB choice in diabetes; leaves open need for RCTs on organoprotection.
Current data on the prevalence of hypertension and diabetes mellitus (DM) are presented. Concomitant DM complicates the course of cardiac diseases, affecting the effectiveness of antihypertensive therapy. Along with high blood pressure, lipid and carbohydrate metabolism parameters should be corrected. Nephroprotection is also important in these patients. These goals are achievable due to the pleiotropic effects of some drugs. The analytical paper reviews the pleiotropic organoprotective effects of the antihypertensive drug azilsartan medoxomil. The data on its antihypertensive efficacy versus other angiotensin II receptor blockers are presented. In addition, the results of clinical trials in patients with various components of the metabolic syndrome (obesity, dyslipidemia, hyperglycemia) and DM are described.
No takes yet. Share an insight, caveat, or question.
Kochergina et al. (2021) conducted a review in Hypertension and diabetes mellitus. Azilsartan medoxomil vs. Other angiotensin II receptor blockers was evaluated. Azilsartan medoxomil demonstrates pleiotropic organoprotective effects and antihypertensive efficacy compared to other angiotensin II receptor blockers in patients with diabetes and metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: